The Role Of Probiotics In The Treatment Of Helicobacter Pylori-Caused Gastritis

Zerihun Asefa Biru

Ethiopian Institute of Agricultural Research, HARC,
Food Science and Nutrition Research directorate,
PO Box 2003, Addis Ababa, Ethiopia
zafuase@gmail.com

Abstract: Helicobacter pylori are a typical bacterium that affects a portion of the population in the world. Probiotics in combination with antibiotics to treat gastritis caused by Helicobacter pylori is an effective treatment that has fewer negative effects than antibiotics alone. In comparison to using antibiotics alone, probiotics plus antibiotic supplementation eliminate gastritis caused by H pylori. Antibiotic-based H. pylori treatment is only about seventy percent successful, and it comes with a slew of side effects. As a result, probiotics combined with antibiotics have a completely inhibiting effect on H. pylori caused by gastritis. Probiotics are beneficial in reducing H. pylori-related stomach discomfort, according to several in vivo investigations. Human studies looked at the efficacy of antibiotics and probiotics in combination, and the results showed that probiotics improved H. pylori gastritis reduction and inhibited H. pylori settlement. Despite this, no study has been able to show that probiotics alone are capable of eliminating H. pylori. Probiotics used in conjunction with antibiotics can reduce the antagonistic qualities induced by H. pylori abolition antibiotic activity, and hence have beneficial properties in H. pylori-infected people. Long-term intake of diets containing probiotic strains improves antibiotic action of H. pylori infection in humans, mostly by lowering the risk of antibiotic-related diseases.

Keywords: Duodenum, Gastritis, Helicobacter pylori, Probiotics, Ulcer**.**

1. Introduction

Helicobacter pylorus is a gram-negative bacterium with curled or curved polar flagella. At the beginning of the 1980s, the organisms were cultured from human gastric biopsies [1]. Bacterial infection is a major risk factor for severe and long-term gastritis and intestinal ulcers [2], [3]. Several in vitro and in vivo molecular and physiological studies have linked H. pylori infection, either directly or indirectly, to the spread of intestinal cancer [4]. [5] confirmed that H. pylori infection was linked to the majority of gastritis disease development. According to [6], chronic gastritis is caused by long-term H. pylori infection. The infection of the bacterium was the leading cause of stomach sores and intestinal abnormalities [7], [8]. According to an [9], epidemiological study, this pylori causes class-I carcinogen for stomach cancer. In developed countries, the rate of infection in adults is 20-50 percent, and in developing countries, the rate is close to 80 percent, which is linked to poor hygiene and living conditions [10], [11]. The likelihood of acquiring the disease increases with age. The infection is commonly acquired during childhood and persists if not properly treated. Infection rates are related to age, civilization, socioeconomic status, hygienic conditions, and the presence of bacteria [12], [13], [14]. The main reservoirs of H. pylori are the human intestine, which is the most likely source of disease transmission from person to person [15]. Infected women are the main source of H. pylori infection in their families, according to an epidemiological study [16]. In humans, the infection is a common cause of duodenal and stomach ulcers, with 13 out of every 20 people infected with the bacterium having an advanced ulcer infection. When the lining of the abdominal cavity is damaged by the acid produced in the stomach, the original flesh becomes revealed. The stomach wall produces hydrochloric acid, which is necessary for food digestion and also kills disease-causing bacteria that are consumed with food. Some cells in the intestine's inner line and the duodenum produce a slimy wall that protects the bell and duodenum's covering from acids. There is usually consistency between the amount of acid you mark and the slimy protection [17]. If this equilibrium is disrupted, acid can damage the abdomen's facing, resulting in a sore. The infection can irritate the lining of the stomach or duodenum in certain people. This is known as gastritis, and it can be caused by a variety of factors, including vitamin B12 deficiency. In gastritis, the slimy protective wall is disrupted in some systems, and the amount of acid produced improves in some cases. This appears to allow the acid to irritate. When given as immunotherapy, a combination of antimicrobials can be cast-off in vivo to remove H. pylori, but none of the antimicrobials are active enough to exterminate the infection [1]. The primary mark suggested H. pylori extermination act consists of a combination of dual or additional antimicrobials and an acid-suppressive medication [18]. However, action with many medications has revealed to be antagonistic properties that lead to the termination of the action [19], as well as imperfect efficiency, primarily in an antimicrobial fight [20].

1.2. Identification of the Infection

The presence of H. pylori infection can be established by hostile and/or non-invasive systems. Esophageal gastroduodenal endoscopy is required for hostile examinations. Endoscopy is used to find operation cases of the abdominal and duodenums, and the analysis of H. pylori is usually completed with urease testing, histology, and/or nation. All of these biopsy-based techniques are unfavorable to patients, carry a small but significant risk of complications, and are prone to sampling inaccuracy and contamination [21],[22]. Non-invasive tests are based on outlier models, with the most commonly used being the quick urea breath examination, fecal antigen testing, and serology [23].

1.3. H. Pylori infection treatments

The H. Pylori disease has decreased to an average of 125 percent in industrialized countries from an average of 60 percent utilizing multi-drug treatment [24]. In contrast, multi-drug antimicrobial action has resulted in an increase in

antibiotic-resistant H. pylori in a majority of the country; for example, in Japan, 40 percent of the infection is resistant to antibiotics clarithromycin and amoxicillin and in Taiwan, 50 percent of the infection is resistant to antibiotics clarithromycin and amoxicillin [12]. In Europe, three-way healing, which combines a proton drive inhibitor (PPI) with two antibiotics (clarithromycin and amoxicillin), is the current standard of care for eradicating H. pylori infection [25]. However, the activity of contagion is hampered by rapid bacterial resistance to drugs, poor compliance, an excessively high bacteria load, impaired mucosal immunity, early re-infection, and the occurrence of intracellular bacteria [26]. As a result, there is less of a need for new H. pylori-specific compounds.

1.4. Probiotics' role againest of H. pylori infection

Probiotics are living microbes such as Lactobacillus spp., Bifidobacterium spp., and S. boulardii these confer a health benefit on the host when administered in adequate amounts [27]. Currently, the most widely used probiotics are lactic acid-producing microbes, primarily Lactobacillus sp. They have been proven to be beneficial in the treatment of a variety of intestinal illnesses, including severe communicable diarrhea and scarcity. Probiotics can be beneficial in H. pylori diseased patients for a variety of reasons. The multi-antibiotic treatment for H. pylori is less than 70 percent effective. However, it is classy and reasons lateral possessions and the advance of antibiotic fighting by H. pylori. Probiotics may now be a low-cost, broad alternative solution for avoiding or reducing H. pylori establishment. Physical studies confirmed that probiotic action reduces H. pylori-related intestinal irritation [28]. The study of [29], also revealed an improvement in H. pylori gastritis and a decrease in concentration after the administration of probiotics. In response to the animal, H. pylori-infected individuals experience mucosal irritation in the abdomen; specific drives develop illness complications, such as an ulcer in the abdominal or proximal duodenum and cancer in either the body or the antrum of the stomach. H. pylori infection extermination is not successful when using antibiotics as monotherapy or dual therapy using mixtures of an acid-suppressing agent and an antibiotic or two antibiotics without acid blockage. [30], discovered that using different Lactobacillus strains reduces H. pylori colonization and Helicobacter-induced gastric inflammation in murine mockups. Oral treatment with the culture-spent supernatant of L. acidophilus strain decreased H. pylori density, reduced H. pylori urease activity, and healed H. pylori-associated mucosal inflammation in unadventurous mice [31]. In precise hygienic mice treated with L. casei, there was a decrease in H. pylori concentration as well as intestinal irritation. The current interest in probiotics as healing agents against H. pylori is motivated not only by clinical data demonstrating the efficacy of probiotics in various gastrointestinal diseases but also by the pathogenic microbes' accumulative resistance to antibiotics and thus patients' increasing interest in alternative therapies. Eradication of the pathogens is required for the management of gastritis-related complications. A proton pump inhibitor, clarithromycin, and amoxicillin are the most commonly recommended standard triple-therapy. This combination has been used for years and is the recommended method for H. pylori eradication[32], [25]. Extermination rates, on the other hand, have been steadily declining over the last decade[33], [34]. Eradication failure rates currently exceed 30% in several countries [35], and extinction disappointment is directly related to antibiotic resistance caused by antibiotic abuse or misuse [36], [37]. Probiotics play a significant role in steadying the intra-gastric micro-ecological situation [38]. Some recent studies have shown that many probiotic strains particularly Lactobacillus sp, Bifidobacterium sp, and S. boulardii have incompatible sound effects both in vitro and in vivo [39]. The study of [40], also suggests that probiotic supplementation as an addition to antibiotics action could recover the disease extinction degrees. Probiotic adjuncts supplemented with triple-therapy improve eradication rates by approximately 41 percent [41]. Probiotic supplementation reduces the lateral effects of H. pylori treatment, such as nausea, vomiting, diarrhea, constipation, epigastric pain, loss of appetite, and abdominal distention, by approximately 80 percent [42].

2. Probiotics inaction appliances

2.1. Mechanisms other than immunology

Non-immunological barriers include the acidity of the stomach and the gastric mucosal barrier, which serve as the primary line of defense against pathogenic bacteria. Major Probiotic accomplishments include epithelial fence improvement, improved bond to colonic mucosa and connected reserve of pathogen bond, competitive elimination of pathogenic microbes, and production of anti-microorganism ingredients [43].

2.1.1. Enhancement of the epithelial barrier

The colonic epithelium is in stable commerce with luminal fillings and variable, enteric flora. The colonic hurdle is the primary defense tool used to maintain epithelial integrity and protect the entity from the situation. It consists of a slimy coating, antimicrobial peptides, secretory IgA, and an intricate epithelial connection linkage [44]. When this fence function is disrupted, pathogenic microbes can penetrate the submucosa and cause inciting reactions, which can lead to colonic illnesses such as inflammatory bowel disease[45]. Probiotic bacteria are required to participate in the colonic fence utility and maintenance. Lactobacilli, for example, inhibit some genes that code for devotion intersection proteins like E-cadherin and β catenin in a T84 cell barrier. Furthermore, lactobacillus affects epithelial fence function by phosphorylating loyalty link proteins and increasing the number of protein kinase C (PKC) isoforms such as PKCδ [46]. Probiotics help to mend the intestinal barrier once it has been damaged to prevent infections from breaching the mucosal barrier. They restore mucosal integrity in T84 by improving the recognition and reallocation of protein kinase close-fitting connection proteins following the remodeling of the tight intersection complex. [47], found that probiotic LAB maintains the epithelial fence and enhances the appearance of close-fitting connection proteins by stimulating the p38 and extracellular regulated kinase motioning pathways in vivo and in vitro. They help to strengthen the mucosal fence by avoiding cytokine-induced epithelium damage, which is linked to the onset of bowel disease [48]. Mucin glycoproteins are the most abundant macromolecular occupants of epithelial slime and have been linked to both health and illness. Probiotics may promote mucous discharge as a means of improving fence usefulness and preventing infections from entering [49]. In human

colonic cell lines, several Lactobacillus species increase mucin appearance [50]). In HT29 cells, the strain of Lactobacillus acidophilus increases MUC2 expression (Kim et al., 2008). In HT29 cells, other Lactobacillus species enhance the abundance of MUC2, MUC3, and MUC5AC [51]. As a result, probiotics boost stomach mucus production.

2.1.2. Pathogen bond embarrassment and improved bond to abdominal Mucosa

Colonic mucosa adhesion is a requirement for colonization and the interface between probiotic bacteria and the host [52]. Probiotic adhesion to the intestinal mucosa is also necessary for inflection of the invulnerability system and pathogen antagonism. One of the most important benefits of probiotics has been their ability to promote adhesion. Lactic acid bacteria (LABs) have a variety of surface determinants that interact with colonic epithelial cells (IECs) and slime in a complex way. IECs release mucin, a complex glycoprotein combination that is the major element of slime, which inhibits pathogenic bacteria' ability to connect [53]. In addition, the mucous gel contains lipids, free proteins, immunoglobulin, and salts [54]. This specific touch has defined a possible association between probiotic microorganisms' exterior proteins and pathogens' competitive banning from the slime. Lactobacillus sp. has proteins that promote slimy adhesion [55], as well as surface adhesion proteins, saccharide moieties, and lipoteichoic acids that facilitate attachment to the mucous layer [55]. Mucus-binding protein generated by Lactobacillus reuteri is the most common slime pointing to bacterial adhesin [56]. This protein consists mostly of secreted and externally linked proteins that are either bound to the skin lipid moiety or embedded in the cell wall and have a function in lactobacilli mucous adherence [57]. It has also helped the human gut migrate by degrading the extracellular matrix of cells or allowing close contact with the epithelium[58]. The binding of probiotics like Lactobacillus reuteri and Lactobacillus fermentum to epithelial mucus is mediated by Mucous adhesion-promoting protein (Mapa)[59]. Enteropathogens are inhibited by MUC2 and MUC3 mucins, which are produced by the probiotic L. Plantarum. These improved slimy coatings and glycocalyx covering the colonic epithelium, as well as probiotics occupying microbial binding sites, protect against pathogen invasion[60]. The combination of probiotics boosted cell surface mucin synthesis and altered mucin gene expression in a way that was dependent on the microbial cells' attachment to the intestinal epithelium [61]. Probiotics also alter the quality of colonic mucins, preventing pathogen binding [60]. Probiotic strains can also cause epithelial cells to secrete defenses (small peptides/proteins), which are dynamic in comparison to bacteria, fungi, and viruses. This helps to keep the intestinal barrier in good shape [62]. In animals, defensins are a class of membrane-disrupting peptides. It is non-specific and is mostly connected to the membrane surface's phospholipid clusters via electrostatic interactions. This contact causes pores in their membranes, which compromise membrane integrity and induce microbial lysis [63]. Passive forces, electrostatic contacts, hydrophobic interactions, steric forces, lipoteichoic acids, and precise structures, such as peripheral adjuncts encapsulated by lectins, all play a role in probiotic adherence to epithelial mucosa [60]. H. pylori can be inhibited by probiotic bacteria. Lactobacilli like Lactobacillus johnsonii and Lactobacillus acidophilus [31] can use their aversive bond activity to release antimicrobial compounds. Furthermore, strains like L. reuteri and W. confusa can prevent H. pylori from developing by interfering with bond sites [64]. It has been proven that L. reuteri prevents H. pylori from binding to specific glycolipid receptors [64]. Nonspecific blockage of receptor sites, on the other hand, is the most likely mechanism by which lactobacilli can disrupt the bonding of a wide range of dangerous bacteria.

2.1.3. Competitive barring of pathogenic microbes

One species of bacteria dynamically strives for receptor sites in the colonic tract other than another species. The mechanisms used by one species of microbes to exclude or reduce the growth of another species are varied, including the mechanisms of making unsuitable microecology, eradication of existing bacterial receptor sites, assembly and emission of antimicrobial constituents and selective metabolites, and competitive exhaustion of vital nutrients [65]. Specific glueyness assets due to the boundary among external proteins and mucins could hinder the settlement of pathogenic bacteria and consequences opposed the activity by some strains of probiotics beside bond of enteropathogens [66]. Competitive barring by colonic microbes is founded on a bacterium-to-bacterium interface interceded by the opposition for existing nutrients and mucosal bond sites. Bacteria can alter their environment to make it less suitable for their competitors to advance a low-cost gain. One example of this type of ecological change is the assembly of antibacterial compounds such as lactic and acetic acid [67]. Some lactobacilli and bifidobacteria bind carbohydrates to specific sites on enteropathogens ((Fujiwara, 2001 #174), allowing strains to compete for receptor sites on host cells with specific pathogens [68], [69]. Using steric disruption at enterocyte pathogen receptors, probiotic strains may often prevent the entry of harmful bacteria [31].

2.2. Antimicrobial ingredients are made at a factory

The production of low molecular weight compounds like organic acids, and antibacterial components like bacteriocins, are two of the techniques used by probiotics to help people feel better. Organic acids, particularly acetic and lactic acids, have a high inhibitory effect against gram-negative bacteria, and they have long been thought to be the principal antimicrobial chemicals responsible for probiotics' inhibitory action against pathogens such as H. pylori [70]. The dissociated organic acid enters the bacterial cell and dissociates inside its cytoplasm, lowering the intracellular pH or increasing the intracellular accumulation of an ionized form of organic acid, which can indicate the bacterial cell's injury [71]. Antibacterial peptides, such as bacteriocins and tiny AMPs, are produced by many LAB. The public mechanisms of bacteriocin-mediated massacre include the obliteration of mark cells by aperture creation and hang-up of cell wall synthesis [72]. Bacteriocin production confers the making strains with an inexpensive benefit indoors in difficult microbial situations as an effect of their antimicrobial activity. Bacteriocin synthesis boosts the dominance of producing strains and allows for direct pathogen growth suppression in the gastrointestinal tract [73]. Lievin, V., et al. [74] reported that two Bifidobacterium strains that generate bacteriocins have a high killing activity against numerous pathogenic bacteria, including H. pylori.

Furthermore, probiotic bacteria can produce de-conjugated bile acids, which are bile salts' byproducts. The antibacterial activity of de-conjugated bile acids is similar to that of the bile salts produced by the host organism. It explains how probiotics fight themselves from bactericidal metabolites they produce [75]. The final yields of lactic acid and hydrogen peroxide by LAB are two other known components released by probiotics [76]. Lactobacilli, on the other hand, have different inhibitory effects on H. pylori strains. The lactic acid generation has been demonstrated to inhibit H. pylori in strains of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus johnsonii, and Lactobacillus lactis. [77], also showed the involvement of protein-based molecules in this inhibitory impact. Other probiotic bacteria, such as Weissella confusa, Lactobacillus lactis, and Bacillus subtilis [78]; [79], have been found to produce bacteriocins that inhibit H. pylori growth in vitro. These components are related to animocumacins, which belong to the isocoumarin category of antibiotics, in B. subtilis [79].

2.2.1. Mechanisms of immunity

Probiotic bacteria can interact with epithelial cells, dendritic cells, monocytes/macrophages, and lymphocytes to exert immunomodulatory effects. The immune system is classified into two types: native and acquired. The acquired immune response is dependent on antigen-specific T cells. The natural immune system, on the other hand, responds to pathogen-associated molecular patterns, which are shared by the vast majority of infections[80]. Configuration respect receptors bind pathogen-associated molecular patterns and communicate signals when bacteria engage with them, triggering the initial response to pathogens[81]. IECs are the most common host cells with which probiotics interact, although probiotics can also be found in DCs, which play an important role in both inborn and acquired immunity. Over their PPRs, both IECs and DCs can interact with gut bacteria and respond to them [80], [81]. TLRs are transmembrane proteins found on B cells, natural killer cells, DCs, macrophages, fibroblasts, epithelial cells, and endothelial cells in the immune system [82]. Viruses and bacteria produce nucleic acid-based PAMPs, which they respond to [80]. The downregulation of TLR expression, the production of metabolites that may prevent TNF-1 from entering blood mononuclear cells, and the preservation of NF B signaling in enterocytes are all ways that probiotics can reduce intestinal inflammation [80]. Over their PPRs, both IECs and DCs can interact with gut bacteria and respond to them [81]. TLRs are trans-membrane proteins found on B cells, natural killer cells, DCs, macrophages, fibroblasts, epithelial cells, and endothelial cells in the immune system. The release of various inciting mediators such as chemokines and cytokines describes the inspirational reaction to intestinal H. pylori poisoning. The release of interleukin 8 (IL-8) signals the migration of neutrophils and monocytes to the mucosa and therefore the cytokine response [83]. Tumor necrosis factor (TNF- α) is produced by stimulated monocytes and dendritic cells in the lamina propria, as well as IL-1 and IL-6. CD4+ T cells (type 1) are stimulated by IL-1 and IL-6, which produce a variety of cytokines such as IL-4, -5, IL-6, and interferon-γ [84]. This response is unable to stop the toxin from irritating. Probiotics can affect the host's immune response by interacting with epithelial cells and altering the excretion of anti-inflammatory cytokines, resulting in a reduction in gastrointestinal irritation and action [85]. L. salivarius inhibits H. pylori-induced IL-8 secretion by gastric epithelial cells, according to in vitro research [86]. Probiotic lactic acid bacteria modulate the immune system primarily by monitoring the balance of pro-inflammatory and anti-inflammatory cytokines, resulting in a reduction in stomach action and irritation. Resulting in probiotic ingestion, a reduction in the assembly of precise IgG antibodies to H. pylori poison in corresponding to the decrease of intestinal irritation was detected in physical studies[86]. Lastly, probiotic ingestion has been stimulating IgA responses, thus leading to a mucosa-stabilizing result and firming the mucosal fence[87]. The impact of probiotics on the immunological response, on the other hand, is difficult to categorize. Because each probiotic strain may elicit a different immunological response, it is important to consider the host's immune prowess[88].

3. Conclusion

Modification of gut microbiota, opposition with pathogens for obedience to the mucosa and epithelium, manufacture of antimicrobial constituents, strengthening of the intestinal epithelial fence nosiness with minimal recognizing nodding, and modulation of the immune system to benefit the host are some of the mechanisms by which probiotics have antagonistic effects on various enteropathogens. Exploration of the medicinal structures of probiotic strains, their methods of exploitation, and tests based on probiotic treatment could be beneficial in the healing of H. pylori and other enteropathogens associated with a variety of disorders. Despite the effectiveness of antibiotic-based therapy, we are concerned about the possibility of antibacterial drug resistance. Furthermore, these medicines' lateral effects are a common source of treatment cessation. Probiotics, regardless of their instrument of an act, could provide a novel approach to the treatment of the bacterium infection. Probiotics can assist to reduce gastritis therapy-related side effects and, in turn, aid in the recovery of the extinction level. Consumption of fermented foods containing probiotic lactic acid bacteria reduces H. pylori concentration and inflammations, according to studies conducted on volunteer individuals. Extinction of H. pylori antibiotics with fermented food including probiotic bacteria could be a noble medicinal strategy to address the poison's unmet treatment needs. Since H. pylori were identified as a major cause of digestive ulcers, gastritis, and abdominal neoplasms, extinction healing has been widely used. The standard triple therapy, which includes a proton pump inhibitor (PPI), clarithromycin, and amoxicillin, has shown to be less effective, with extinction rates as low as 50 to 70 percent, especially in areas where clarithromycin resistance is common. H. pylori resistance to clarithromycin and levofloxacin increased from 8.6 to 20.7 percent and from 10.3 to 32.5 percent, respectively. In the long run, the high levels of antibiotic-associated lateral effects may result in worse patient satisfaction. The administration of probiotics to children and families has been suggested as a way to speed up H. pylori eradication and reduce the negative effects of PPI-based eradication therapy. Probiotics were introduced immediately after the start of triple healing and were prescribed for one to four weeks in most educations. The Lactobacillus families of probiotics have been shown to prevent H. pylori from colonizing the stomach and binding to its glycolipid receptors.

4. References

[1]. Kusters, J.G., A.H. Van Vliet, and E.J. Kuipers, Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews, 2006. 19(3): p. 449-490.

[2]. Stamatis, G., et al., In vitro anti-Helicobacter pylori activity of Greek herbal medicines. Journal of ethnopharmacology, 2003. 88(2-3): p. 175-179.

[3]. Shin, I.S., H. Masuda, and K. Naohide, Bactericidal activity of wasabi (Wasabia japonica) against Helicobacter pylori. International Journal of Food Microbiology, 2004. 94(3): p. 255-261.

[4]. Erim, T., et al., Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World journal of surgery, 2008. 32(9): p. 2021-2025.

[5]. Uemura, N. and S. Okamoto, Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterology Clinics of North America, 2000. 29(4): p. 819-827.

[6]. Dooley, C.P., et al., Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. New England journal of medicine, 1989. 321(23): p. 1562-1566.

[7]. Kashiwagi, H., Ulcers and gastritis. Endoscopy, 2003. 35(01): p. 9-14.

[8]. Plummer, M., S. Franceschi, and N. Muñoz, Epidemiology of gastric cancer. IARC scientific publications, 2004(157): p. 311-326.

[9]. Ohata, H., et al., Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. International journal of cancer, 2004. 109(1): p. 138-143.

[10]. Frenck Jr, R.W. and J. Clemens, Helicobacter in the developing world. Microbes and infection, 2003. 5(8): p. 705-713.

[11]. Rothenbacher, D. and H. Brenner, Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes and Infection, 2003. 5(8): p. 693-703.

[12]. Aguemon, B., et al., Prevalence and risk-factors for Helicobacter pylori infection in urban and rural Beninese populations. Clinical microbiology and infection, 2005. 11(8): p. 611-617.

[13]. Syam, A.F., et al., Risk factors and prevalence of Helicobacter pylori in five largest islands of Indonesia: A preliminary study. PloS one, 2015. 10(11): p. e0140186.

[14]. Brigitte, S., et al., RNA interactomics: recent advances and remaining challenges. F1000Research, 2018. 7.

[15]. Vaira, D., et al., The transmission of Helicobacter pylori from stomach to stomach. Alimentary Pharmacology & Therapeutics, 2001. 15: p. 33-42.

[16]. Weyermann, M., et al., The mother as source of Helicobacter pylori infection. Epidemiology, 2006: p. 332-334.

[17]. Hemaiswarya, S., et al., Mechanism of action of probiotics. Brazilian archives of Biology and technology, 2013. 56(1): p. 113-119.

[18]. Malfertheiner, P., et al., Current concepts in the management of Helicobacter pylori infection—The Maastricht 2-2000 Consensus Report. Alimentary pharmacology & therapeutics, 2002. 16(2): p. 167-180.

[19]. Peyrin–Biroulet, L., et al., Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology, 2008. 6(6): p. 644-653.

[20]. Gerrits, M.M., et al., Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. The Lancet infectious diseases, 2006. 6(11): p. 699-709.

[21]. Logan, R.P. and M.M. Walker, ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ: British Medical Journal, 2001. 323(7318): p. 920.

[22]. Gatta, G., et al., Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. European journal of cancer, 2003. 39(15): p. 2214-2222.

[23]. Lionetti, E., et al., Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter, 2010. 15(2): p. 79-87.

[24]. Balcázar, J.L., et al., The role of probiotics in aquaculture. Veterinary microbiology, 2006. 114(3-4): p. 173-186.

[25]. Malfertheiner, P., et al., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007. 56(6): p. 772-781.

[26]. Broutet, N., et al., Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients. Alimentary pharmacology & therapeutics, 2003. 17(1): p. 99-109.

[27]. Grajek, W., A. Olejnik, and A. Sip, Probiotics, prebiotics and antioxidants as functional foods. Acta Biochimica Polonica, 2005. 52(3): p. 665-671.

[28]. Tanih, N., et al., Helicobacter pylori infection in Africa: Pathology and microbiological diagnosis. African Journal of Biotechnology, 2008. 7(25).

[29]. Chauviere, G., et al., Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. Microbiology, 1992. 138(8): p. 1689-1696.

[30]. Mitchell, P., et al., Helicobacter pylori induces in-vivo expansion of human regulatory T cells through stimulating interleukin-1β production by dendritic cells. Clinical & Experimental Immunology, 2012. 170(3): p. 300-309.

[31]. Coconnier, M.-H., et al., Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Applied and Environmental Microbiology, 1998. 64(11): p. 4573-4580.

[32]. Chey, W.D., B.C. Wong, and P.P.C.o.t.A.C.o. Gastroenterology, American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Official journal of the American College of Gastroenterology| ACG, 2007. 102(8): p. 1808-1825.

[33]. Graham, D.Y. and L. Fischbach, Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 2010. 59(8): p. 1143-1153.

[34]. Malfertheiner, P., et al., Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet, 2011. 377(9769): p. 905-913.

[35]. Vítor, J.M. and F.F. Vale, Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunology & Medical Microbiology, 2011. 63(2): p. 153-164.

[36]. Zullo, A., et al., Effects of Helicobacter pylori eradication on early stage gastric mucosa–associated lymphoid tissue lymphoma. Clinical gastroenterology and hepatology, 2010. 8(2): p. 105-110.

[37]. Wu, C.-Y., et al., Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology, 2010. 28(18).

[38]. Iqbal, M.Z., et al., Probiotics and their beneficial effects against various diseases. Pakistan journal of pharmaceutical sciences, 2014. 27(2).

[39]. Gotteland, M., O. Brunser, and S. Cruchet, Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Alimentary pharmacology & therapeutics, 2006. 23(8): p. 1077-1086.

[40]. Wilhelm, S.M., J.L. Johnson, and P.B. Kale-Pradhan, Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Annals of Pharmacotherapy, 2011. 45(7-8): p. 960-966.

[41]. Lü, M., et al., Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PloS one, 2016. 11(10): p. e0163743.

[42]. Mohan, B.P., et al., Convolutional neural networks in the computer-aided diagnosis of Helicobacter pylori infection and non-causal comparison to physician endoscopists: a systematic review with meta-analysis. Annals of gastroenterology, 2021. 34(1): p. 20.

[43]. Klaenhammer, T.R., Genetics of bacteriocins produced by lactic acid bacteria. FEMS microbiology reviews, 1993. 12(1-3): p. 39-85.

[44]. Ohland, C.L. and W.K. MacNaughton, Probiotic bacteria and intestinal epithelial barrier function. American journal of physiology-gastrointestinal and liver physiology, 2010. 298(6): p. G807-G819.

[45]. Hooper, L.V., et al., Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nature immunology, 2003. 4(3): p. 269-273.

[46]. Hummel, T.Z., et al., Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. Journal of pediatric gastroenterology and nutrition, 2012. 54(6): p. 753-757.

[47]. Dai, S., et al., Effects of lactic acid bacteria-fermented soymilk on isoflavone metabolites and short-chain fatty acids excretion and their modulating effects on gut microbiota. Journal of food science, 2019. 84(7): p. 1854-1863.

[48]. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology, 2006. 3(7): p. 390-407.

[49]. Bermudez-Brito, M., et al., Probiotic mechanisms of action. Annals of Nutrition and Metabolism, 2012. 61(2): p. 160-174.

[50]. Mack, D.R., et al., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut, 2003. 52(6): p. 827-833.

[51]. Otte, J.-M., E. Cario, and D.K. Podolsky, Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology, 2004. 126(4): p. 1054-1070.

[52] Schiffrin, E.L., M.L. Lipman, and J.F. Mann, Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007. 116(1): p. 85-97.

[53]. González-Rodríguez, I., et al., Role of extracellular transaldolase from Bifidobacterium bifidum in mucin adhesion and aggregation. Applied and environmental microbiology, 2012. 78(11): p. 3992-3998.

[54]. Neutra, M., Gastrointestinal mucus: synthesis, secretion, and function. Physiology of the gastrointestinal tract, 1987: p. 975-1009.

[55]. Mukherjee, S., et al., Quantitative appraisal of the probiotic attributes and in vitro adhesion potential of anti-listerial bacteriocin-producing lactic acid bacteria. Probiotics and antimicrobial proteins, 2013. 5(2): p. 99-109.

[56]. Vélez, M.P., et al., Identification and characterization of starter lactic acid bacteria and probiotics from Columbian dairy products. Journal of Applied Microbiology, 2007. 103(3): p. 666-674.

[57]. Sanchez, M., et al., Effect of Lactobacillus rhamnosus CGMCC1. 3724 supplementation on weight loss and maintenance in obese men and women. British Journal of Nutrition, 2014. 111(8): p. 1507-1519.

[58]. Candela, M., et al., Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. International journal of food microbiology, 2008. 125(3): p. 286-292.

[59]. Ouwehand, A.C., S. Salminen, and E. Isolauri, Probiotics: an overview of beneficial effects. Lactic acid bacteria: genetics, metabolism and applications, 2002: p. 279-289.

[60]. Kim, E.K. and E.-J. Choi, Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2010. 1802(4): p. 396-405.

[61]. Caballero-Franco, C., et al., The VSL# 3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2007. 292(1): p. G315-G322.

[62]. Furrie, E., Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome? Nature Clinical Practice Gastroenterology & Hepatology, 2005. 2(7): p. 304-305.

[63]. Bals, A. and U. Kulozik, The influence of the pore size, the foaming temperature and the viscosity of the continuous phase on the properties of foams produced by membrane foaming. Journal of Membrane Science, 2003. 220(1-2): p. 5-11.

[64]. Mukai, A., et al., Nocardithiocin, a novel thiopeptide antibiotic, produced by pathogenic Nocardia pseudobrasiliensis IFM 0757. The Journal of antibiotics, 2009. 62(11): p. 613-619.

[65]. Rolfe, G., D. Freshwater, and M. Jasper, Critical Reflection for Nursing and the Helping Professions a User's Guide. 2001.

[66]. Servin, A.L., Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS microbiology reviews, 2004. 28(4): p. 405-440.

[67]. Schiffrin, E. and S. Blum, Interactions between the microbiota and the intestinal mucosa. European journal of clinical nutrition, 2002. 56(3): p. S60-S64.

[68]. Fujiwara, M. and H. Caswell, Demography of the endangered North Atlantic right whale. Nature, 2001. 414(6863): p. 537-541.

[69] . Mukai, T., et al., Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology & Medical Microbiology, 2002. 32(2): p. 105-110.

[70]. Makras, L., et al., Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Research in Microbiology, 2006. 157(3): p. 241-247.

[71]. Russell, R., et al., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis international, 2008. 19(6): p. 733-759.

[72]. Hassan, S.F. and R.A. Rosen, Resolving the ghost problem in nonlinear massive gravity. Physical review letters, 2012. 108(4): p. 041101.

[73]. O'Shea, J.J. and R. Plenge, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity, 2012. 36(4): p. 542-550.

[74]. Lievin, V., et al., Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut, 2000. 47(5): p. 646-652.

[75]. Oelschlaeger, T.A., Mechanisms of probiotic actions–a review. International journal of medical microbiology, 2010. 300(1): p. 57-62.

[76]. van den Bergh, W.M., et al., Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery, 2003. 52(2): p. 276-282.

[77]. Vizoso Pinto, M.G., et al., LuMPIS–A modified luminescence-based mammalian interactome mapping pull-down assay for the investigation of protein–protein interactions encoded by GC-low ORFs. Proteomics, 2009. 9(23): p. 5303-5308.

[78]. Nam, K.H. and J. Li, BRI1/BAK1, a receptor kinase pair mediating brassinosteroid signaling. Cell, 2002. 110(2): p. 203-212.

[79]. Kim, J., H.-K. Chung, and C. Chae, Association of porcine circovirus 2 with porcine respiratory disease complex. The Veterinary Journal, 2003. 166(3): p. 251-256.

[80]. Gómez-Llorente, C., S. Munoz, and A. Gil, Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proceedings of the Nutrition Society, 2010. 69(3): p. 381-389.

[81]. Lebeer, S., J. Vanderleyden, and S.C. De Keersmaecker, Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews Microbiology, 2010. 8(3): p. 171-184.

[82]. Miriam, M., Diminishing demandingness of parents; children with recurrent infections. Health, 2012. 2012.

[83]. Arakawa, T., Regulation of acid secretion and peptic ulcer formation by inflammatory cytokines. The Immunobiology of H. pylori-From Pathogenesis to Prevention, 1997. 183.

[84]. Goodyear-Smith, F., et al., Immunization in the print media—Perspectives presented by the press. Journal of health communication, 2007. 12(8): p. 759-770.

[85]. Johnston, N., et al., Cell biology of laryngeal epithelial defenses in health and disease: further studies. Annals of Otology, Rhinology & Laryngology, 2003. 112(6): p. 481-491.

[86]. Kabir, S., Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter, 2009. 14(3): p. 159-171.

[87]. Vitini, E., et al., Gut mucosal immunostimulation by lactic acid bacteria. Biocell: official journal of the Sociedades Latinoamericanas de Microscopia Electronica... et. al, 2000. 24(3): p. 223-232.

[88]. Haller, D., et al., Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut, 2000. 47(1): p. 79-87.

Author profile

Zerihun Asefa received BSc in Applied Biology from Adama Science and Technology University in 2013 and MSc in Microbial,Cellular and Mulecular Biology(Applied Microbiology) from Addis Ababa University in 2018. During 2014- 2022 he has worked in Ethiopian Institute of Agricultural Research, Food Science and Nutrition Directorate as Food and Nutrition researcher.